



BIOS 522: Survival Analysis Methods

#### Lecture 9:

## Parametric regression models


# Semiparametric regression


• Cox proportional hazards regression


$$h_i(t) = h_0(t) \exp(\beta_1 X_{i1} + \dots + \beta_k X_{ik})$$


pependent permade is a function

•  $h_0(t)$  can take any of an infinite number of shapes









2


# Parametric regression


• Parametric proportional hazards regression


$$h_i(t) = h_0(t) \exp(\beta_1 X_{i1} + \dots + \beta_k X_{ik})$$

Basetine no tend

•  $h_0(t)$  takes the shape of a pre-specified distribution







Shape

#### Parametric PH model structure

• Exponential PH model

$$h_i(t) = \lambda_0 \exp(\beta_1 X_{i1} + \dots + \beta_1 X_{ik})$$

· Weibull PH model

$$h_i(t) = \lambda_0 \gamma_0 (\lambda_0 t)^{\gamma_0 - 1} \exp(\beta_1 X_{i1} + \dots + \beta_1 X_{ik})$$


4

B's are log ratios

# Coefficients for parametric PH

• Example: Weibull proportional hazards model

$$h_i(t) = \lambda_0 \gamma_0 (\lambda_0 t)^{\gamma_0 - 1} \exp(\beta_1 X_{i1} + \dots + \beta_k X_{ik})$$




• 
$$\hat{\beta}_1, \dots, \hat{\beta}_k$$

• Estimate reference group parameters:

• Weibull rate 
$$\hat{\lambda}_0$$
, Weibull shape  $\hat{\gamma}_0$ 

Recall: liketimood from for right-consored data: lat now also include rate & shape  $L(\lambda_0,\gamma_0,\beta_1,...,\beta_k) = parameters$ 

$$\prod\nolimits_{i=1}^{n}[h(T_{i}^{*}|\lambda_{0},\gamma_{0},\beta_{1},\ldots,\beta_{k})]^{\delta_{i}}S(T_{i}^{*}|\lambda_{0},\gamma_{0},\beta_{1},\ldots,\beta_{k})$$





# Piecewise exponential model


$$h_i(t) = h_0(t) \exp(\beta_1 X_{i1} + \dots + \beta_k X_{ik})$$

Can model more complex shapes

• The baseline hazard function  $h_0(t)$  is modeled as constant within intervals








# Estimation for parametric PH

• Example: piecewise exponential model

$$h_i(t) = h_0(t) \exp(\beta_1 X_{i1} + \dots + \beta_k X_{ik})$$

- Estimate log hazard ratios:
  - $\hat{\beta}_1, \dots, \hat{\beta}_k$
- Estimate reference group parameters:
  - Hazard rates  $\hat{\lambda}_1, \dots, \hat{\lambda}_6$



#### RESEARCH ARTICLE

Open Access

# Piecewise exponential models to assess the influence of job-specific experience on the hazard of acute injury for hourly factory workers

Jessica Kubo<sup>1\*</sup>, Mark R Cullen<sup>2</sup>, Linda Cantley<sup>3</sup>, Martin Slade<sup>3</sup>, Baylah Tessier-Sherman<sup>3</sup>, Oyebode Taiwo<sup>3</sup> and Manisha Desai<sup>1</sup>

<u>Goal</u>: To define an approach for studying the relationship between experience and risk of injury for different occupations.

<u>Population</u>: Data set of 81,301 hourly production workers of a global aluminum company at 207 facilities.

8

Outcome variable: Time in months from the start of a particular job to injury on that job.

Non-injured employees were censored at the earliest of the following: change of job within the corporation, death, termination from the company, or the end of the observation period.

#### Predictor variables:

Age at job initiation, overall company tenure at job initiation, gender, race, physical demand of the job, union status of the plant, plant type, and socio-demographic characteristics.



<u>Statistical analysis</u>: Sought to model the hazard of injury as a function of time on the job (i.e. experience). The main parameter of interest was the **baseline hazard itself**. They wanted to assess whether the hazard for injury changes with experience (is the hazard constant over time?). Thus, a Cox PH was not appropriate.


#### Compared several models:

- Exponential PH model (constant baseline hazard)
- Weibull PH model
- · A piecewise exponential model with one cut point at 12 months
- A piecewise exponential model with one data-driven\* cut point

\* Yielded the largest likelihood value

10

Results: Figure 2 compares model-predicted survival functions and KM estimate for a test set \$1,301 employees



# Results: Table 5 reports results for the 2-piece exponential model with 19 month cut point

Table 5 Results from CC and MI frailty models for 2-piece exponential model with 19 month cut point (data-driven model)

	Complete case analysis (N=33 427 jobs for 13 427 employees)		Multiple imputation (N=191 692 jobs for 81 301 employees)	
	HR (95% CI)	P-value	HR (95% CI)	P-value
0-19 Months (inexperienced period)	1.41 (1.35, 1.47)	<.001	1,33 (1.29, 1.36)	<.001
Male gender	0.62 (0.57, 0.68)	<.001	0.71 (0.68, 0.73)	<.001
Non-White	1.08 (0.99, 1.17)	0.070	0.97 (0.93, 1.00)	0.067
First job at company	0.88 (0.79, 0.98)	0.017	0.90 (0.88, 0.93)	<.001
Age at start of job	0.98 (0.98, 0.99)	<.001	0.99 (0.98, 0.99)	<.001
Physical demand	1.25 (1.21, 1.29)	<.001	1.26 (1.24, 1.29)	<.001
Smelter plant	1.24 (1.17, 1.32)	<.001	1.30 (1.24, 1.36)	<.001
Union plant	1.16 (1.04, 1.28)	0.006	1.30 (1.23, 1.38)	<.001
Original plant	1.01 (0.83, 1.22)	0.942	1.57 (1.50, 1.65)	<.001



12

## Accelerated failure time models

• AFT model:

as long twile

 $T_i = e^{\alpha_1 X_{i1} + \dots + \alpha_k X_{ik}} T_0$ 

Covariates operate to lengthen or shorten survival time

Survival time random variable in the reference group

#### Accelerated failure time models

 $S_i(t) = S_0 \left( e^{-(\alpha_1 X_{i1} + \dots + \alpha_k X_{ik})} t \right)$ 

• AFT model (written another way):

Requires that you set a distribution.

Refine if here k(t) We this

Survival function in the reference group

Covariates operate to "speed up" or "slow down" time


We could assume Weibull, exponential etc.


14


### Accelerated failure time models


• Consider two groups, defined by  $X_i = 1$  vs.  $X_i = 0$ 

• If the **acceleration factor**  $\exp(\alpha) = 2$ , then:











15

### Inference for the AFT model



#### Interence for the AFT model






- Null hypothesis  $H_0$ 
  - · Covariate has no effect on survival
  - The acceleration factor  $\exp(\alpha_i) = 1$
  - Equivalently, the coefficient  $\alpha_j=0$

Don't have hazard ratios:
We have
acceleration factors
instead

16

#### Acceleration factors ≠ hazard ratios

<u>~</u>	Coefficient	Acceleration factor	Survival in group 1 versus group 0
(4)	$\alpha > 0$	$\exp(\alpha) > 1$	Increased survival; age slower
D	$\alpha = 0$	$\exp(\alpha)=1$	No difference in survival
9	$\alpha < 0$	$\exp(\alpha) < 1$	Decreased survival; age faster





### Acceleration factors ≠ hazard ratios

- In general, AFT and PH models are different
  - Log-logistic AFT model ≠ log-logistic PH model
- For some *particular* parametric distributions, the models are related
  - Exponential AFT model is also a PH model
  - · Weibull AFT model is also a PH model
- Acceleration factors are not just inverted hazard ratios\*

\* exception = exponential AFT model

1

#### Prediction with the AFT model

- Given our acceleration factor(s)  $\hat{\alpha}_1, \dots, \hat{\alpha}_k$  and our fitted reference group parameters  $\hat{\lambda}_0$  and  $\hat{\gamma}_0$ , making **predictions** with the AFT model is easy
- For any set of covariates, we can quickly generate predictions for  $S_i(t)$ ,  $h_i(t)$ ,  $H_i(t)$ , median survival time, mean survival time, etc.
- More in today's activity...

# Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials

Joanna Dobson, Richard J Whitley, Stuart Pocock, Arnold S Monto

<u>Goal</u>: Estimate efficacy of **oseltamivir** (Tamiflu) for alleviation of influenza symptoms

<u>Population</u>: Meta-analysis of nine randomized, placebo-controlled trials of 75 mg twice a day oseltamivir in adults. Total data set included **4328 patients**.

Eligible patients were within 36 hours of symptom onset, with fever and at least two influenza symptoms.

20

Outcome variable: The primary outcome was **time to alleviation of all symptoms** (all seven influenza symptoms scored as absent or mild) and remained so for at least 21.5 hours

The **time origin** was time of first study drug intake.

#### Predictor variables: Trial arm.

- Clinical trial.
- Age (<65 yrs, ≥65 yrs).
- Risk status (based on age, presence of chronic illness).
- Time from influenza onset to randomization (<24 hrs, ≥24 hrs).
- Symptom score at randomization.
- Virus type (influenza A or B).

#### Statistical analysis: Two sets of analyses were conducted:

- 1. Using the **intention-to-treat population**, including all trial participants who received at least one dose of study drug.
- 2. Using the **intention-to-treat infected population**, including all trial participants as above + confirmed to be influenza-infected.

"For time to alleviation of all symptoms, we initially assessed Kaplan-Meier plots by treatment group and we obtained a treatment effect estimate (time ratio) from a log-logistic accelerated failure time model, adjusted for trial. We did not use proportional hazards models because non-proportionality of hazards was evident.

We estimated treatment differences in median time to alleviation of symptoms adjusted for trial along with **bootstrap confidence intervals** (2000 repetitions, stratified by trial and treatment group)."

22

<u>Results</u>: **Figure 1** reports the acceleration factor (time ratio) for each trial and overall in the **intention-to-treat infected population**.




Figure 1: Fixed effect meta-analysis for time to alleviation of all symptoms

The overall time ratio is calculated from an accelerated failure time model adjusted for trial.

**Abstract:** "In the intention-to-treat infected population, we noted a **21% shorter time to alleviation of all symptoms** for oseltamivir versus placebo recipients (**time ratio 0.79**, 95% CI 0.74-0.85; p<0.0001).

The median times were **97.5 h** for oseltamivir and **122.7 h** for placebo groups (difference - 25.2 h, 95% CI -36.2 to -16.0)."

# **Figure 2** assessed the overall fit of the model by comparing Kaplan-Meier curves and AFT predictions.




Figure 2: Overall Kaplan-Meier curves and estimated survival curves from AFT model (adjusted for trial) by treatment group for time to alleviation of all symptoms in all trials combined AFT=accelerated failure time.

**Results:** "The accelerated failure time model provided a good fit to the data (figure 2)."

Conclusion: Oseltamivir in adults with influenza accelerates time to clinical symptom alleviation, supporting the beneficial effect of this widely used drug

24

Cox PH model	Parametric regression models
(+) Widely used in the literature	(-) Less commonly used in the literature
(+) Flexible baseline hazard function; no prespecification required!	(-) Necessary to pre-specify shape of baseline hazard function
(+) Model fits even if baseline hazard function dies not have a parametric shape	(-) Baseline hazard function may fit poorly and negatively impact the model; need to <b>justify your assumptions</b> !
(-) Slightly less efficient (larger standard errors) when a parametric model fits well	(+) Slightly more efficient (smaller standard errors) when parametric model fits well
(-) Unstable when data are sparse	(+) When <b>data are sparse</b> , these gains in efficiency are more noticeable
(-) We use this model to study hazard ratios only, not the	(+) This model is better suited to study the shape of the
actual hazard functions	hazard functions, not just the hazard ratios
(-) Need specialized estimators (e.g. Breslow estimator) to use model to predict survival	(+) Straightforward to use model to <b>predict survival</b>
(-) May not be well-suited to complex settings	(+) Can be generalized to <b>model complex settings</b> , like jointly modeling several correlated survival outcomes